—
C+
C+ The full Closelook — membership. Open the C+ overview

Biomerieux SA (BIM.PA) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Biomerieux SA

BIM.PA in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Biomerieux designs, makes and sells in-vitro diagnostic systems used to detect infections and monitor microbial contamination. It runs two segments, clinical applications for hospitals and industrial applications for food, pharmaceutical and cosmetic quality control, covering instruments such as blood-culture systems, PCR panels, mass-spectrometry identification units and automated antimicrobial-susceptibility testers. The company is based in Marcy-l'Étoile, France, and sells across Europe, the Americas, Africa, the Middle East and Asia Pacific.
Where it sits in the stack
Biomerieux carries no seat in our index and sits outside the AI build-out coverage; it belongs to the diary's wider healthcare universe, in the diagnostics and research sleeve.
Who it is priced against
The diary holds no assigned peer group for this name; the comparison the market most often draws is with Roche's diagnostics division.
Why Closelook tracks it
Biomerieux is not a constituent of any Closelook index, carries no Closelook score yet, and has not appeared in the diary's quoted editions.
What the diary watches
The diary watches whether the shares recover from the current distance below the 200-day average and the 52-week high, as a sign of renewed interest in the diagnostics sleeve.

Biomerieux SA (BIM.PA) trades on the PA exchange in France.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for BIM.PA, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Biomerieux SA (BIM.PA)?

Biomerieux SA trades as BIM.PA on the PA exchange (France) in the Closelook research universe, as of the registry build of 2026-09-18.

Is BIM.PA in a Closelook index?

Not currently — Biomerieux SA is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does BIM.PA trade against its moving averages?

Downtrend stack: Trades -0.8% vs the 50-day and -14.1% vs the 200-day average, 37.4% below the 52-week high and +9.9% off the 52-week low. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Biomerieux SA do?

Biomerieux designs, makes and sells in-vitro diagnostic systems used to detect infections and monitor microbial contamination. It runs two segments, clinical applications for hospitals and industrial applications for food, pharmaceutical and cosmetic quality control, covering instruments such as blood-culture systems, PCR panels, mass-spectrometry identification units and automated antimicrobial-susceptibility testers. The company is based in Marcy-l'Étoile, France, and sells across Europe, the Americas, Africa, the Middle East and Asia Pacific. The diary holds no assigned peer group for this name; the comparison the market most often draws is with Roche's diagnostics division.

Where does Biomerieux SA sit in the AI build-out?

Biomerieux carries no seat in our index and sits outside the AI build-out coverage; it belongs to the diary's wider healthcare universe, in the diagnostics and research sleeve. Biomerieux is not a constituent of any Closelook index, carries no Closelook score yet, and has not appeared in the diary's quoted editions.

What does this page show?

A live price chart with SMA overlays and drawing tools for BIM.PA, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe